Skip to the story
All StoriesPoliticsConflict & SecurityBusiness & EconomyScience & TechHealthClimateMedia
All stories
Health25 outlets ran this3 min read

FDA abortion pill review to continue into next year

Agency provides court-ordered update on safety study of mifepristone

AI-assisted coverage comparison, editor-supervised · How this was made

Published
FDA abortion pill review to continue into next year

What this story says

  • The Food and Drug Administration's safety review of the abortion pill mifepristone will continue into next year.
  • The FDA provided a court-ordered update on its progress in a legal filing on Wednesday.
  • The agency expects to finish a safety study by mid-December and issue a report on findings no later than March 2027.
  • Abortion opponents have criticised the timeline, while the FDA was directed to provide the update by a federal appeals court.

Who covered it

Left 70%(16)Centre 26%(6)Right 4%(1)

Percentages are shares of the 23 outlets carrying a published leaning rating. 2 of the 25 outlets we know ran this story carry no rating and are not counted in them. Coverage measured .

Trust

42/100

Craft

59/100

Hype

41/100

25 sources · methodology

Thin on the right so far

Only 1 of the 23 outlets with a published leaning rating that ran this story are rated right.

This story is still being watched, so it is a count and not yet a finding. Coverage keeps arriving for hours after an event, and a side that has published nothing this morning may publish by tonight. If it is still true when we stop checking, we will say so plainly.

The Food and Drug Administration (FDA) has stated that its safety review of mifepristone, the nation's primary abortion pill, will continue into next year. This timeline was communicated in a legal filing submitted late Wednesday, fulfilling a court order. The agency anticipates completing a safety study of the drug by mid-December of this year. A report detailing the findings is expected to be released no later than March 2027, after which the FDA will determine whether to implement any new restrictions or modifications to the drug's use.

The FDA was directed to provide this update by a federal appeals court in New Orleans. This directive stems from a legal case brought by the state of Louisiana, which alleges that the mail delivery of mifepristone conflicts with the state's abortion ban. Mifepristone was first approved by the FDA in 2000 and has had its restrictions eased over time, including the removal of a requirement for in-person dispensing.

Disagreement on timeline for report

While ABC News, The Independent, and The Independent (US) report that a report on the findings is expected no later than March 2027, The Hill states the FDA revealed it won't publish its mifepristone safety review until March 2027. NBC News and NBC Dallas-Fort Worth report the FDA says it will complete the safety review in March, with NBC Dallas-Fort Worth specifying the review will be completed in March.

What the coverage left out

None of the left-rated digests mention the specific criticism from Gavin Oxley of Americans United for Life that the administration is 'clearly uninterested in mitigating the ongoing harms caused by the abortion pill'. The right-rated digest does not mention the FDA's expected completion date for the safety study (mid-December this year) or the expected date for the report on findings (no later than March 2027).

Tags:#AbortionPill#FDA#Mifepristone#WomensHealth#CourtOrder

Still developing. We have re-checked which outlets are covering this 1 time, most recently on 8 Oct 2026, 05:00, and will add the sides that appear.

How each side covered it

Our own reading of the reporting listed below, written from the outlets’ articles rather than quoted from them. The reasoning is set out on our methodology page.

Left

16 rated outlets

  • Fifteen left-rated reports noted that the FDA's safety review of the abortion pill mifepristone will continue into next year. These reports stated that the FDA provided a court-ordered update on its progress in a legal filing late Wednesday. They also included that the agency expects to complete a safety study by mid-December this year and that a report on the findings is expected no later than March 2027. Several of these reports mentioned that the FDA was directed to provide the update by a federal appeals court in New Orleans, overseeing a case brought by the state of Louisiana. ABC News, the only full report in this category, also included criticism from Gavin Oxley of Americans United for Life, who called the move a lack of 'true leadership' and stated the administration was 'on the wrong side of women's health'.

Centre

6 rated outlets

  • Six centre-rated reports highlighted that the FDA's safety review of the abortion pill mifepristone will continue into next year. These reports noted the FDA provided a court-ordered update on its progress in a legal filing late Wednesday. They also mentioned the agency expects to complete a safety study by mid-December this year and that a report on the findings is expected no later than March 2027. The Hill, a centre-rated outlet, reported that the FDA revealed it won't publish its mifepristone safety review until March 2027, sparking criticism from both sides.

Right

1 rated outlet

  • The single right-rated report, a statement from SBA Pro-Life America, focused on the upcoming court-ordered deadline for the FDA's mifepristone study update. It quoted SBA Pro-Life America President Marjorie Dannenfelser referencing Dr. Heidi Overton's commitment to conduct an abortion drug study. This report did not mention the timeline for the completion of the safety review or the expected date for the report on findings.

Questions about this coverage

How did the left and right cover FDA abortion pill review to continue into next year?
Of the 23 outlets on this story carrying a published leaning rating, 70% are rated left, 26% are rated centre, 4% are rated right. Those percentages are shares of the rated outlets, not of every outlet that ran it, which was 25. The sections above set out what each side emphasised, in its own terms.
Is FDA abortion pill review to continue into next year left or right?
The story itself is neither. What can be counted is who has covered it, and 70% of the 23 rated outlets on it are rated left — so far this is a story carried mostly by the left. Coverage is still arriving and that can change, which is why the figure is dated rather than fixed.
Is the coverage of FDA abortion pill review to continue into next year biased?
FDA abortion pill review to continue into next year is one event reported by 25 outlets, and this page does not rate the story as biased or unbiased. What it publishes is the spread: which outlets ran it, where named rating organisations place each of them on the spectrum, and what each side chose to lead with. A leaning rating describes an outlet's record over time, not this article, and the two should not be run together.
Which side is not reporting FDA abortion pill review to continue into next year?
When we first saw this story, outlets rated right had barely covered it. Coverage accretes for hours after an event, so that is where to look rather than a verdict — the split above is the current count, and it is the one to read.
Which outlets covered FDA abortion pill review to continue into next year?
25 that we know of, every one of them listed further up this page with a link to its own report and to what we hold on the publisher. Nothing here is a summary of somebody else's summary: the outlets are named so the original reporting can be read.
When will the FDA complete its safety review of the abortion pill?
The Food and Drug Administration expects to complete a safety study of the abortion pill mifepristone by mid-December this year. A report on the findings is anticipated no later than March 2027, after which the agency will decide on potential new restrictions or changes to the drug's use.
Why did the FDA provide an update on the abortion pill review?
The FDA provided the update in a legal filing late Wednesday because it was ordered to do so by a federal appeals court in New Orleans. This directive is part of a lawsuit brought by the state of Louisiana, which is challenging the mail delivery of mifepristone.
What is the timeline for the FDA's report on the mifepristone safety review?
The FDA expects to complete its safety study of mifepristone by mid-December this year. A report detailing the findings from this study is expected to be published no later than March 2027.

Read it at the source

25 outlets, grouped by the leaning a published rating gives them. Every headline links to the original; an underlined outlet name opens our profile of that publisher.

Left

16
Show 8 more

Centre

6

Right

1

Not rated

2

How did this read?

About the coverage, not about the story. We do not ask whether you agree with what happened — we have no honest use for that answer.

More in Health

All Health →
Credit: Following NYC from Pexels3 min readAbortion bans linked to higher health insurance costs for women, study findsRead story

Elsewhere on the site

Former Taiwan President Tsai Ing-wen speaks at Stanford DEFCON 2026 on Wednesday. Photo courtesy of the Office of Tsai Ing-wenPolitics•3 min readTsai Ing-wen highlights Taiwan's tech role in Indo-Pacific stabilityPresident Donald Trump speaks during a news conference with Elon Musk in the Oval Office of the White House, Friday, May 30, 2025, in Washington. (AP Photo/Evan Vucci)Politics•3 min readTrump to Award Medals to Musk and Tech LeadersLincoln University students sue Missouri for $549 million over alleged underfundingPolitics•3 min readLincoln University students sue Missouri for $549 million over alleged underfundingIowa Council Meeting Opens With Satanic PrayerPolitics•3 min readIowa Council Meeting Opens With Satanic Prayer
FDA mifepristone review update | MediaBias News